ESSO 43 | Achieving textbook outcomes with neoadjuvant targeted therapy in borderline resectable melanoma
Anna Czarnecka
• 2 Oct 2024
Anna Czarnecka, MD, PhD, Maria Skłodowska-Curie Institute of Oncology, Warsaw, Poland, discusses the impressive outcomes achieved through neoadjuvant–adjuvant targeted therapy in borderline resectable stage IIIB–D and IV melanoma, where nearly 80% of patients reached textbook results, significantly benefiting overall and recurrence-free survival. She emphasizes the critical role of skilled surgeons in determining long-term patient survival, underscoring the importance of a multidisciplinary approach in treating melanoma. This interview took place at the ESSO 43 congress in Antwerp, Belgium.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
